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Reply to S. Zucker
We recently demonstrated that increased interleukin (IL)-6 pro-
duction in Hodgkin’s lymphoma is associated with an induction of
hepcidin, which contributes to the iron-restricted anemia of chronic
disease often observed at Hodgkin’s lymphoma diagnosis.1 Our data
also suggested that increased hepcidin levels might not be sufficient for
induction of anemia and that other mechanisms, possibly induced by
IL-6, might be responsible. On the basis of well-founded reasoning,
Zucker proposes in his letter that compensation by increased erythro-
poietin production may be the missing link to explain the lack of
anemia, despite increased hepcidin levels.2 Inappropriately high
erythropoietin levels have been described as a compensation mecha-
nism in hereditary spherocytosis with a reduced erythroid life span
and without anemia.3 Zucker points out that IL-6 is a potential stim-
ulator of erythropoietin as shown in a cell line model by Faquin et al.4
In this model, however, IL-6–induced erythropoietin stimulation was
hypoxia-dependent and was not observed under normoxic condi-
tions. In the tumor tissue, local hypoxia is present in a proportion of
patients with Hodgkin’s lymphoma, as suggested by necrotic areas
resulting in the release of increased levels of circulating cell-free DNA.5
However, systemic hypoxia from anemia is considered the major
stimulus for renal erythropoietin synthesis.
Applying the reasoning of Zucker to patients with Hodgkin’s
lymphoma, one would expect apparently inappropriate high erythro-
poietin levels in patients without anemia to compensate for the
hepcidin-induced iron restriction. There are few data on erythropoi-
etin levels in patients with Hodgkin’s lymphoma at diagnosis. Pohl et
al6 reported slightly, although not significant, higher serum erythro-
poietin levels in patients with nonanemic Hodgkin’s lymphoma when
compared with control, whereas erythropoietin levels in patients with
anemia appeared to be adequate.
Zucker mentions the well-documented effect of erythropoietin
on downregulation of hepcidin,7,8 even in the presence of inflamma-
tion,9,10 which indicates that erythropoietin trumps hepcidin as mas-
ter regulator of erythropoiesis under conditions of inflammation.
Continuing with this idea, one would expect that hepcidin levels
should be lower than those observed in our patients without anemia.
In conclusion, we agree that erythropoietin as a master regulator of
erythropoiesis could probably be another player in the complex sce-
nario of Hodgkin’s lymphoma anemia, which may be the result of
opposing effects between stimulators and inhibitors of erythropoiesis
and proteins involved in iron metabolism and iron-sensing pathways.
The scenario remains open for other potential pathways to be defined.
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